In summary, our results show that targeting HER2 protein to activated DCs in situ significantly enhances anti-tumor T-cell immunity, and we propose that this strategy provides a feasible approach for immunotherapy in patients with cancer. This evidence concerns the gene ERBB2 and neoplasm.